An Alzheimer’s Win: How Lilly Designed Donanemab Trial To Succeed

Phase II Results May Support Accelerated Approval

 
• By Mandy Jackson
  
Brainstorming creative idea
Lilly CEO David Ricks outlined the path to Phase II success for donanemab in Alzheimer's disease • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D